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Abstract: Hemophilia patients with inhibitors faced the constraint of inadequate treatment for 
several years before the era of recombinant factor VIIa (rFVII). Initially, rFVIIa was used in the 
compassionate-use programs. After a worldwide license was issued, more than 1.5 million doses 
were administered. Bleeding of joints and muscles was controlled effectively by means of an 
early home treatment program, with either a standard dose of 90 µg/kg every 2 to 3 hours for a 
few doses or a single dose of 270 µg/kg. For more serious bleeding episodes or minor surgery, 
an initial dose of 90 µg/kg was given every 2 hours for 24 to 48 hours followed by increased 
intervals of 3 to 6 hours according to the severity of bleeding and efficacy of bleeding control. 
In cases of major surgery such as orthopedic procedures, the same regimen can be applied 
except for a higher initial dose of 120 to 180 µg/kg. However, increasing the dose should be 
considered if there are unexpected bleeding complications since the half-life and clearance of 
rFVIIa differ between individuals. In addition, prophylaxis is administered to a small number 
of patients. Finally, the reported thromboembolic events found in hemophilia patients with 
inhibitors receiving rFVIIa are extremely low, much less than 1%.
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Introduction
Among patients with hemophilia, 85% to 90% have hemophilia A and 10% to 15% 
have hemophilia B. The risk of developing inhibitors differs; 25% to 30% of hemophilia 
A patients develop inhibitors to factor VIII clotting activity,1,2 while only 1% to 3% of 
hemophilia B patients develop inhibitors to factor IX clotting activity.3 There are two 
types of inhibitors: low responding and high responding. Low-responding inhibitors 
occur in approximately 20% to 50% of patients with hemophilia. These patient usu-
ally have inhibitor titers below 5 Bethesda units (BU) and, when re-exposed to factor 
concentrates, do not mount an anamnestic response. Low-responding inhibitors may 
be transient and disappear spontaneously. They can be treated with a higher dose of 
factor concentrates. However, some of these may convert to high-responding over time. 
Therefore, careful monitoring should be done periodically. In contrast, inhibitor levels 
in high responders will rise markedly after being exposed to factor concentrates. Most 
patients with high-responding inhibitors have titers greater than 10 BU, although if they 
have not been re-exposed to factor concentrates for some time, baseline titers may be 
lower. The treatment in these patients is more problematic. Hemophilia patients with 
inhibitors risk increased morbidity and mortality compared with noninhibitor patients. 
If inadequately treated, the frequent joint bleeds will lead to synovial inflammation and 
hypertrophy, and predisposition to recurrent bleeding with progressive damage to the Journal of Blood Medicine 2010:1 38
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inhibitors”, “hemophilia and inhibitors to FVIII or FIX”, 
“congenital hemophilia and inhibitors”. Only English language 
literature was considered and publications included only those 
in which patients had inhibitors to factor VIII or factor IX and 
were treated with rFVIIa.
Compassionate-use programs
Recombinant factor VIIa was available on an emergency- and 
compassionate-use basis from 1988 to 1999 for the open-label 
treatment of hemophilia patients with inhibitors to factor VIII 
or factor IX for life-threatening hemorrhage and hemostasis 
maintenance during surgery when alternative therapies were 
unavailable or had already failed to stop bleeding or when 
complications were foreseen. The treatment was provided on 
a named-patient basis with a series of case reports. In most 
studies, the efficacy of rFVIIa in producing hemostasis was 
evaluated using a global assessment by the physician, the 
patient, or the patient’s caregiver. The precise definitions 
used varied between trials but generally, categories such 
as excellent, effective, partially effective, or ineffective 
were included. The assessment took into account relief of 
pain/tenderness, improved joint mobility, size of the bleed, 
and/or cessation of bleeding. The overall effective response 
to rFVIIa at the dose ranging from 60 to 120 µg/kg after 
8 and 24 hours in the first 55 consecutive bleeds was 91% 
and 90%, respectively.11 Recombinant factor VIIa has been 
given since 1988 to hemophilia patients with inhibitors suf-
fering from life- and limb-threatening bleeds in the central 
nervous system, intraperitoneum and retroperitoneum, as 
well as muscle and joint bleedings. The higher dose (around 
90 µg/kg) given every 2 to 3 hours was more effective than 
lower dosages in more serious bleeding situations.12
Data on the use of rFVIIa in the treatment of serious 
  nonsurgical bleeding from the noncomparative compassionate- 
and emergency-use programs have shown that the response 
was rated as excellent or effective in 62% to 86% of bleeding 
episodes following treatment with rFVIIa.8,13–17
Independent published reports
Efficacy of nonsurgical bleeding control
Trials of rFVIIa in hemophilia patients with inhibitors include 
dose-finding studies and home treatment studies. An initial, 
randomized, double-blind, dose-finding multicenter study 
included 179 joint, muscle, and mucocutaneous bleeding 
episodes in 78 patients treated with two dosages of rFVIIa 
(35 and 70 µg/kg intravenously every 2 to 3 hours). It dem-
onstrated that the two dosages were similarly effective.18 
cartilage and subchondral bone.4 These patients will suffer 
from chronic pain requiring frequent hospital visits. They will 
need devices for facilitating mobility such as wheelchairs 
and crutches. Also, they will be absent from work and school 
which results in poor health-related quality of life.5
The aim of management of hemophilia patients with 
inhibitors is to control the bleeding episodes and to eradicate 
the inhibitors by immune tolerance therapy. However, 
immune tolerance therapy is not always successful. As 
a result, various elective surgeries were often delayed or 
  canceled due to inadequate hemostatic achievement. In 
1983, Hedner and Kisiel reported the successful use of 
human plasma derived factor VIIa in the treatment of two 
hemophilia patients with high-titer inhibitors.6 Subsequently, 
the recombinant factor VIIa (rFVIIa; NovoSeven®; Novo 
Nordisk) was derived from cultured hamster kidney cells 
using recombinant DNA technology. The development of 
rFVIIa has opened a new era for hemophilia patients with 
inhibitors. It has low risk of transfusion-transmitted disease 
compared to plasma-derived hemostatic agent. Moreover, 
rFVIIa has not exhibited immunogenicity in hemophilia 
A and B patients. It has shown effective hemostasis during 
joint, muscle and soft tissues bleeding7 as well as minor and 
major surgeries.8 There are two mechanisms of action of high-
dose FVIIa: 1) tissue factor independent thrombin generation 
on the activated platelets, resulting in the formation of tight 
hemostatic fibrin plugs resistant to premature lysis,9 and 
2) FVIIa overcoming competition with zymogen FVII for 
binding to tissue factor to form factor VIIa-tissue factor 
complex with subsequent activation of other coagulation 
factors to generate thrombin.10 The rFVIIa was used on the 
compassionate-use programs during 1988 to 1999 and sub-
sequently licensed for the treatment of hemophilia patients 
with inhibitors in Europe in 1996, Asia in 1997 to 1998 and 
North America in 1999.
This paper reviews experience with rFVIIa in the 
  treatment of hemophilia patients with inhibitors from the 
compassionate- and emergency-use programs and from 
independent published reports from 1988 to 2009.
Materials and methods
For the independent relevant publications assessed in this 
paper, a literature search (PubMed) from January 1988 through 
November 2009 was used to identify independent reports 
of hemophilia patients with inhibitors treated with rFVIIa. 
The search terms including “activated factor VII”, “rFVIIa”, 
“recombinant activated FVII”, “NovoSeven” and “rhFVIIa” 
were used with each of the following: “hemophilia with Journal of Blood Medicine 2010:1 39
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However, a substantial delay before start of treatment (about 
7.5 hours longer in the 70 µg/kg group) may have contributed 
to the lack of difference in efficacy between the two groups. 
Among hemarthroses, the global response to treatment was 
excellent or effective in 71% of each dosage group and the 
mean number of doses per episode of bleeding was 3.1. 
Data from the compassionate-use programs suggested that a 
higher dose (around 90 µg/kg) given every 2 to 3 hours was 
more effective than lower dosages in more serious bleeding 
situations.12
The effect of early treatment as well as regular treatment 
several times per week in preventing the development of 
long-term arthropathy is well documented.19 Early treatment 
with rVIIa is more likely to be associated with a successful 
outcome than late treatment.20 To facilitate an early initiation 
of treatment, rFVIIa was studied in a home treatment setting. 
Recombinant factor VIIa was administered at a dosage of 
90 to 100 µg/kg every 2 to 4 hours and treatment had to be 
initiated within 8 or 12 hours of the onset of bleeding.20–22 
After about two doses, the hemostatic response was rated 
as excellent or effective in 79% to 93% of bleeding epi-
sodes. After initial resolution, bleeding recurred within 
24 to 48 hours in 4% to 5% of episodes.
In one of the noncomparative home treatment studies, the 
risk of an ineffective or a partially effective response was sig-
nificantly lower if treatment was started within 6 hours of the 
onset of bleeding than if it was started later (odds ratio 0.24; 
95% CI 0.09, 0.63).20 Combined analyses of data from a dose-
finding study, home treatment study, and compassionate use 
study confirmed the benefits of early treatment for patients 
with acute hemarthrosis23 or intramuscular hemorrhage.24 
Fewer doses were needed and higher response rates were 
achieved when treatment was initiated early. Therefore, in a 
home treatment setting, rFVIIa was effective in controlling 
mild to moderate bleeding episodes in hemophilia patients 
with inhibitors.
Recently, it was shown that the use of higher doses for the 
treatment of acute bleeding episodes, to achieve full hemo-
static effect after one single dose of rVIIa, is a convenient, 
safe, and effective, alternative to the repeated dose regimen 
for hemophilia patients with inhibitors.25–31 The effectiveness 
of treatment with a single dose of rFVIIa 270 µg/kg is similar 
to that of a standard regimen (90 µg/kg every 3 hours for 
3 doses) in hemophilia patients with inhibitors experiencing 
hemarthroses.25–27 The outcomes were similar for the single 
270 µg/kg dose and the standard regimen in terms of the treat-
ment response rate, as assessed by patients after 9 hours (25 to 
65% versus 31 to 70%, respectively), and the proportion of 
patients not requiring additional hemostatic medication to 
control a bleeding episode (91% and 92% versus 86% and 
91%).25,26 In the open-label study, in which patients were 
not required to use all three doses of the standard regimen 
unless necessary, the median number of injections used for 
this regimen was three and so the median quantity of rFVIIa 
administered was the same as for the single-dose regimen 
(270 µg/kg per bleeding episode).27
The use of high doses of rFVIIa is also supported by an 
analysis of data from a registry of hemophilia patients with 
inhibitors, which found that bolus doses 200 µg/kg were 
associated with a significantly higher bleed-cessation rate 
than seen with lower doses (97% of 119 bleeds versus 84% 
of 436 bleeds; P  0.01).32 Successful use of bolus doses as 
high as 300 µg/kg has been reported.33
A single dose of 270 µg/kg rFVIIa is of particular benefit 
for patients with poor venous access, frequent target-joint 
hemorrhage, and needle phobia. The single-dose treatment 
regimen may improve patient compliance, enhance the ease 
of home treatment, and facilitate earlier control of hemor-
rhagic events.
Two randomized, open-label, crossover studies compar-
ing rFVIIa with activated prothrombin complex concentrates 
(aPCC) in the home treatment of hemophilia patients with 
inhibitors have been reported.26,34 Prior to these two studies, 
a number of studies, most of them single-arm studies and 
none of them directly comparing rFVIIa and aPCC, have 
investigated the efficacy of these two agents.
The main finding of the FENOC (FEIBA NovoSeven 
Comparative) study was that rFVIIa (2 doses of 90–120 µg/kg) 
and aPCC (1 dose of 75–100 IU/kg) appear to exhibit a 
similar effect on joint bleeds.34 The primary endpoint was 
the proportion of patients reporting effective or partially 
effective hemostasis at 6 hours after treatment initiation. 
Six hours after infusion, the rate of effective plus partially 
effective responses was 78.7% for rFVIIa versus 80.9% for 
aPCC (90% CI –11.4%–15.7%; P = 0.059). The efficacy 
of the two treatments was rated differently by a substantial 
proportion of patients at all time points up to 48 hours. The 
percentage of discordant pairs (one treatment effective and 
the other not effective) ranged from 9.8% to 43.8% at dif-
ferent time points, but was highest during the first 12 hours 
after treatment. Although the objective of this study was to 
demonstrate equivalence between both products, the sta-
tistical criterion to declare both products to be equivalent 
was not met.
In the second trial, two different regimens of rFVIIa 
(a single dose of 270 µg/kg and a regimen of 3 doses of Journal of Blood Medicine 2010:1 40
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90 µg/kg at 0, 3 and 6 hours; administered in double-blind 
fashion) were compared with a single dose of aPCC 75 IU/kg 
  (administered unblinded).26 No statistically significant dif-
ference was found between treatment groups with both the 
binary global response algorithm (P = 0.17) and the trichoto-
mous global response (P = 0.09). However, a trend towards 
increased response was observed in the rFVIIa groups com-
pared with the aPCC group using both global responses. The 
proportion of patients needing additional “rescue” hemostatic 
therapy within the first 9 hours was also significantly lower 
with the single 270 µg/kg dose of rFVIIa treatment than with 
aPCC (8.3% versus 36.4%; P = 0.03), and likewise it was 
lower in the standard 3-dose regimen of rVIIa compared 
with the aPCC group, although statistical significance was 
not reached (9.1% versus 36.4%; P = 0.07).
Analysis using a unified Bayesian meta-regression model 
has suggested that a typical rFVIIa (90 µg/kg every 3 hours) 
will resolve joint bleeding more effectively than a typical 
aPCC regimen (75 IU/kg every 12 hours) after 12, 24 and 
36 hours.35 A systematic review of the cost-effectiveness 
of rFVIIa and aPCC in the treatment of minor/moderate 
  bleeding episodes for hemophilia patients with inhibitors has 
also suggested that rFVIIa may be a cost-effective alternative 
to treatment with aPCC. In 7 of 9 studies, rFVIIa had a lower 
average treatment cost.36
Continuous infusion of rFVIIa
Continuous rFVIIa infusion is a feasible method for the 
treatment of both nonsurgical37 and surgical bleeding38–41 
because of its 100% stability and safety, documented by 
sterility for 3 days at room temperature after being recon-
stituted with diluents.42 The clearance of continuous rFVIIa 
infusion, calculated by clearance (mL/kg/h) = infusion rate 
(IU/kg/h)/plasma level (U/mL), increases in children com-
pared to adults and remains the same level over the time of 
treatment.43 The amount of 1200 µg rFVIIa is equivalent to 
60,000 IU. The median clearance in adults was 56 mL/kg/h 
and 86 mL/kg/h in children.44 Therefore, continuous rFVIIa 
infusion to maintain a required level depends on an individ-
ual’s clearance of rFVIIa. Normally, the estimated infusion 
rate of 16.5 µg/kg/h can raise the plasma level closed to 
10 U/mL. This level is widely considered as an acceptable 
minimal value to maintain hemostasis.40,43,45 The advantages 
of continuous infusion included the 50% reduction of rFVIIa 
requirements when compared with the bolus injection and 
the stability of activity during infusion.39
Most of the protocols of continuous rFVIIa infusion 
start with a rFVIIa bolus at a dose of 90 µg/kg initially 
and every 2 hours during surgery, followed by continuous 
  infusion to maintain a plasma level above 10 U/mL. However, 
during the first 2 to 3 days after surgery, the level of rFVIIa 
was suggested to be maintained at a higher value of 24 to 
56 U/mL. Then, the level was gradually decreased until the 
suture was stitched off. The range of total treatment duration 
in elective surgery was reported at 1 to 34 days.38,41,43,44,46,47 
The effectiveness of this treatment in a prospective cohort 
study, mainly of spontaneous bleeding cases, was around 
80%. However, the difference in response was the bleed-
ing at the mucosal surface, found to be effective in only 
1 of 7 patients.48 The difference in response was hypoth-
esized to be due to the high fibrinolytic activity in the oral 
cavity, which can be counterbalanced by the activation of 
thrombin activatable fibrinolysis inhibitor (TAFI) stimulated 
by bolus injection. In patients with elective surgery, the 
effectiveness in controlling bleeding symptoms was around 
33% to 85% depending on individual studies. Nonetheless, 
bleeding complications could be effectively controlled by 
additional bolus rFVIIa injection with the dose range of 
60 to 90 µg/kg. The difference in response was due to the 
types and aggressiveness of surgery, complications after 
surgery such as infection, the adjuvant of other hemostatic 
agents such as tranexamic acid and the dose of rFVIIa used 
during treatment (Table 1).37–44,46,48–50
To prevent unexpected bleeding, the sequential treat-
ment with bolus and continuous infusion was successfully 
reported in a patient with hip arthroplasty. A bolus injection 
of 150 µg/kg was given at the start of surgery followed by 
120 µg/kg every 2.5 hours for the first 2 days and 90 µg/kg 
every 3 hours for the third day. Then, continuous infusion 
was subsequently administered for the rest of the treatment 
course.49
Similar to other factor concentrates, the prevention of 
thrombophlebitis is required. Standard heparin and low-
molecular-weight heparin (LMWH) were studied by adding 
to the rFVIIa solution. The result showed that the rFVIIa 
activity in the standard heparin mixture was decreased 
by 50% within 4 days.42,51 Therefore, parallel infusions of 
standard heparin or normal saline or adding LWMH to the 
mixture can be used to prevent thrombophlebitis.40
Hemostasis for major surgery
Major surgery includes exploratory laparotomy, surgery in 
the vital organs such as brain, heart and lungs, and orthopedic 
procedures of bone fixation for fractures, hip and knee arthro-
plasty, arthrodeses, open synovectomy, osteotomy, pseudotu-
mor removal and hardware such as plates and intramedullary Journal of Blood Medicine 2010:1 41
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nail removal.52 The earliest major surgical procedure of an 
open knee joint synovectomy in a hemophilia patient with 
inhibitors using rFVIIa was first reported by Hedner et al 
in 1988.53 Ingerslev et al have shown the effectiveness of 
12 hemophilia patients with inhibitors undergoing surgery by 
giving a mean dose of rFVIIa 99 µg/kg every 2 to 3 hours for 
up to 2 days after which dosage intervals were prolonged.54 
The results revealed excellent responses in 11 cases and an 
effective response in one case.
A prospective, double-blind, randomized trial that com-
pared 2 doses of rFVIIa (35 and 90 µg/kg) in hemophilia 
patients with inhibitors who were undergoing 18 minor and 
11 major surgeries was reported in 1998.9 Bolus injections 
of rFVIIa were given every 2 hours for the first 48 hours. 
Thereafter, the same dose was given every 2 to 6 hours for 
an additional 3 days. A significant difference in efficacy in 
terms of maintaining postoperative hemostasis favoring the 
high-dose group was observed from day 3 onward, although 
both doses were similarly effective intraoperatively.
Moreover, an international series of 108 cases of elective 
surgeries performed in nine hemophilia centers worldwide 
was published in 2004. However, only 17 major orthopedic 
surgeries under the cover of rFVIIa were included in the 
series. The outcome revealed 14 good results, 1 fair result 
and 2 poor outcomes.55 Furthermore, a case report56–58 
and case series59–61 of major surgeries among hemophilia 
patients with inhibitors using rFVIIa ranging from 90 to 
300 µg/kg every 2 hours in the first 24 hours followed by 90 
to 120 µg/kg with prolonged intervals of 3 to 6 hours have 
gradually been reported, with effective response rates rang-
ing from 66% to 100%.
In 2009, a consensus protocol for the use of rFVIIa in 
elective orthopedic major surgeries in hemophilia patients 
with inhibitors was published.62 It was based on a review 
of published data and the personal experience of a group 
of expert physicians in Europe. According to the recom-
mendations, major surgeries should be performed at a 
comprehensive hemophilia center with the availability of 
expert physicians in the morning, early in the week. Other 
protocols were given as follows. It is essential for the expert 
physicians to closely monitor the patient for a few days after 
the surgery. An initial bolus dose of rFVIIa in the range of 
120 to 180 µg/kg is given at the start of surgery followed 
by 90 µg/kg at 2-hour intervals throughout surgery. A final 
intraoperative bolus should be given just prior to final 
reduction in the case of hip arthroplasty or release of the 
tourniquet in the case of knee arthroplasty. After 48 hours 
of 2-hour boluses, the dosing intervals may be increased to 
3 hours for the following 48 hours and to 4 hours for the next 
72 hours. At day +8 after the surgery, the intervals between 
doses may be lengthened to 6 hours. The topical applica-
tion of a fibrin sealant during the intraoperative period is 
helpful in minimizing capillary oozing. Additionally, the 
concomitant administration of an antifibrinolytic agent such 
as tranexamic acid is recommended, unless there is a strong 
contraindication. It may enhance the effect of rFVIIa and 
improve hemostasis.51 In cases of bleeding complications 
after the surgery, the next scheduled dose of rFVIIa should be 
brought forward and a dose increase should be considered or 
an additional 5 doses of 90 µg/kg of rFVIIa should be given 
every 2 hours until the hemostasis is achieved. If the measures 
are not been successful, changing treatment to aPCC should 
be considered. Importantly, the postoperative physiotherapy 
should be covered by a bolus of rFVIIa. These protocols 
have been used in 10 major orthopedic surgeries involving 
13 procedures in 5 comprehensive care centers. The intra-
operative hemostasis was satisfactorily achieved; however, 
2 cases were reported of postoperative bleeding. The first 
case had bleeding in the knee 5 days after arthroplasty. The 
patient did not receive tranexamic acid perioperatively and 
the bleeding resolved after the dose of rFVIIa was increased. 
The second case exhibited bleeding 8 hours after shoulder 
arthroplasty. The patient had received tranexamic acid and 
the bleeding gradually resolved 5 days after switching the 
treatment to aPCC. The cost of medication to cover this type 
of surgery was approximately US$750,000 which is 10 times 
greater than that for a person without inhibitors.52,62 Although 
solving the problem in the target joint initially is costly, it 
will decrease the tendency for further frequent bleeding in 
that target joint and also decrease the frequency of bleeding 
in other joints such as the shoulders or elbows if the patient 
has to use crutches for the next 5 to 9 years.63
Sequential/concomitant therapy 
of rFVIIa and aPCC
An initial strikingly excellent response of hemophilia patients 
with inhibitors to rFVIIa after aPCC treatment was observed 
by Key et al.64 The possible synergy between rFVIIa and 
aPCC in vivo and in vitro was demonstrated in 3 patients. It 
might be due to the presence of activated clotting factors in 
the aPCC prior to rFVIIa administration. Sequential therapy 
of rFVIIa and aPCC was reported among ten children who 
had failed their home treatment with rFVIIa and aPCC alone 
(n = 9),65,66 and refractory bleeding to the treatment of rFVIIa 
(n = 1).67 They received alternating doses of rFVIIa (80 to 
225 µg/kg/dose) and aPCC (35 to 80 IU/kg/dose) every Journal of Blood Medicine 2010:1 43
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6 hours; and 1 to 3 doses of rFVIIa were given every 2 hours 
between aPCC doses. Hemostasis was achieved and no 
thromboembolic (TE) event was detected. However, such 
patients should be hospitalized and under the supervision of 
experts in hematology to guard against the risk of TE com-
plication. Antifibrinolytic agents should be avoided.
Recently, Martinowitz et al reported the use of concomi-
tant infusions of low doses of rFVIIa (30 to 70 µg/kg/dose) 
and aPCC (20 to 30 IU/kg/dose) in 5 adult hemophilia A 
patients with inhibitors (8 to 1300 BU), aged 17 to 60 years 
who were refractory to rFVIIa administration.68 They 
exhibited a total number of 400 bleeding episodes, mainly 
hemarthrosis with excellent hemostasis; they required 1 dose 
of concomitant therapy if initiated early after onset of bleed-
ing for 1 to 2 hours, and 2 to 3 doses daily every 6 hours for 
some target joints and large hematoma. The concomitant 
therapy every 6 hours for 24 hours followed by 3 times daily 
and thereafter 2 times daily for a total of 72 hours has been 
successfully used for papilotomy and gallbladder stent inser-
tion. No adverse events and no disseminated intravascular 
coagulation were observed following these infusions.
Prophylaxis with rFVIIa
Prophylaxis in hemophilia patients with inhibitors is not 
generally recommended due to the concern of efficacy, 
TE complications, and cost. The first report described the 
use of a daily dose of 240 µg/kg in a hemophilia B patient 
with high titers during the perioperation and postopera-
tive intensive physical rehabilitation for the correction of 
a knee contracture.69 To date, rFVIIa prophylaxis has been 
reported in 45 hemophilia patients with inhibitors as shown 
in Table 2.69–75 Of note, 22 patients were included in a ran-
domized, double-blind study of receiving daily prophylaxis 
of rFVIIa 90 µg/kg or 270 µg/kg for 3 months.72 The fre-
quencies of bleeding episodes were significantly reduced by 
45% and 59% during the prophylaxis with 90 and 270 µg/kg, 
respectively (P  0.0001) compared to on-demand therapy. 
However, no significant difference was detected between the 
doses. Interestingly, the reduction of bleeding episodes was 
maintained during the postprophylaxis period. The effec-
tiveness of giving pharmacological doses of rFVIIa used 
in the prophylaxis can be explained by the hypothesis that 
the extravascular diffusion of rFVIIa will be available at the 
site of injury. It could contribute to the hemostatic plug by 
increasing thrombin generation on activated platelets.76
Since the frequency of bleeding episodes during prophy-
laxis was significantly reduced, the days of hospitalization, 
absences from work and school, and equipment to increase 
mobility were significantly reduced, which led to marked 
improvement of health and related quality of life com-
pared with on-demand therapy.77 No TE complication was 
reported. However, the cost derived from prophylaxis is more 
expensive than the prior therapy with factor VIII concentrate 
but cheaper than the prior immune tolerance therapy.
Prophylaxis with rFVIIa is a potential option for prevent-
ing episodes of joint bleeding and protecting joint damage 
while awaiting a decline in inhibitor titers before immune 
tolerance therapy can be initiated. Moreover, an interna-
tional survey of attitudes towards secondary prophylaxis 
with rFVIIa in hemophilia A patients with inhibitors was 
conducted by interviewing 31 physicians from hemophilia 
centers and 20 health care providers in Europe and the US.78 
The results revealed a positive attitude and more support for 
secondary prophylaxis in children than in adults.
Thromboembolic complications
Reports on TE complications related to the use of rFVIIa in 
hemophilia patients with inhibitors are rarely found. From 
1996 to 2003 over 700,000 doses (90 µg/kg) were given, there 
have been 25 TE events found in hemophilia patients with 
inhibitors and acquired hemophilia patients.79 An additional 
800,000 doses of rFVIIa have been administered from 2003 
to 2006 during which time a total of 30 TE events and 6 TE 
event-associated fatal events occurred among hemophilia 
patients with inhibitors and acquired-hemophilia patients.80 
Two additional studies reviewed the MedWatch pharmaco-
vigilance program of US Food and Drug administration for 
TE adverse events occurring in patients administered rFVIIa 
in the period from April 1999 through June 2002 and from 
March 25, 1999 through December 31, 2004. The first study81 
reported 67 TE adverse events in rFVIIa recipients compared 
to 16 events in aPCC (FEIBA®) recipients in hemophilia 
patients with inhibitors and acquired hemophilia patients. 
The incidence rate ratio of 2.98 (CI 1.71–5.52) suggested 
the higher TE occurrence in rFVIIa than aPCC recipients. 
The second study82 reported 185 TE events described in 
168 reports. One hundred and nine reports described TE 
events occurring mainly in unlabeled uses for bleeding in 
nonhemophilia patients (n = 92) and occurring less often in 
hemophilia patients (n = 17). Additional 59 reports described 
TE events occurred in nonhemophilia patients enrolled in 
postlicensure trials of unlabeled uses. The TE events involved 
cardiovascular accidents (n = 39), acute myocardial infarc-
tion (n = 34), other arterial thromboses (n = 26), pulmonary 
embolism (n = 32), other venous thromboses including 
deep vein thrombosis (n = 42), and clotted devices (n = 10). Journal of Blood Medicine 2010:1 44
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Table 2 Patient characteristics, regimen, duration and number of bleeding at pre-prophylaxis and prophylaxis period
Year  Author  Hemophilia 
A/B (case)
Inhibitor 
(BU)
Age 
(yr)
Dose of 
rFVIIa
Duration  Number of bleeds 
              Pre-prophylaxis Prophylaxis
Secondary prophylaxis
2001 Cooper 
et al69
B (1) 12.9 13 240 µg/kg 
every 6–24 h
80 days a 2/80 daysb
2001 Saxon 
et al70
A (1) 16 4 90 µg/kg/d 21 weeks 2.1/week 0.4/week
2005 Young 
et al71
A (1) 1.1–2.5 3 200 µg/kg 
every 6–8 h
12 months 32/14 months 7/12 months
B (1) 50–100 15 200 µg/kg 
every 12 h
25 months 2.2/month 0.8/month
2007 Konkle 
et al72
A (10), 
B (1)
2 18 (n = 9) 90 µg/kg/d 3 months 5.6/month 3.0/month
18 (n = 2)
A (11) 2 18 (n = 7) 
18 (n = 4)
270 µg/kg/d 3 months 5.3/month 2.2/month
2007 Morfini 
et al73
A (12), 
B (1)
5 18 (n = 10) 
18 (n = 3)
200–250 µg/kg/  
week to 
220 µg/kg/d
4–48 months 0.25–8.33/month 0–2.25/
month
Primary prophylaxis
2008 Jimenez-Yuste 
et al74
A (1) 9.4 3 90 µg/kg/d 15 months 3/3 years 1/15 months
2009  Jimenez-Yuste 
et al75
A (5)  11–440  2  90–100 µg/kg/d  9 months  4/2 years  1/9 months 
Notes: aWheelchair-bound with bilateral knee contracture of 30 degrees; bTraction and casting/wedging procedures were successfully achieved with only 2 trauma-related 
bleeding episodes.
Seventy-three (52%) of 144 patients with time information 
in the first 24 hours after the last rFVIIa infusion for which 
30 events occurred within 2 hours. Limited data were avail-
able for concomitant risk factors and the underlying medical 
conditions of the patients, which complicates the analysis. 
Nevertheless, the average risk of a TE event was approxi-
mately 3.75 per 100,000 infusions.80 The majority of events 
were found in off-label use and with concomitant hemostatic 
agents such as the sequential use of rFVIIa and aPCC.83 
Ultimately, the incidence of TE events with the use of rFVIIa 
in hemophilia patients with inhibitors was extremely low, 
much less than 1%, and appeared unrelated to dose. No TE 
event was ever found in any hemophilia patient receiving a 
single high dose of 270 µg/kg of rFVIIa.
For continuous infusion, the dose is lower than that of 
bolus injection; therefore, the activation of the hemostatic 
system would be less than that of the bolus injection. The acti-
vation of hemostasis was demonstrated in 4 patients receiv-
ing continuous infusion over 4 to 18 days. The prothrombin 
fragments (F1 + 2) and D-dimer were increased after bolus 
injection and unchanged throughout the treatment period of 
continuous infusion without clinical thromboembolism.50
Discussion
The development of inhibitors to factor VIII and factor IX 
is one of the most challenging complications found among 
hemophilia patients. Less than optimal treatment and lack 
of prophylaxis lead to chronic arthropathy, deformity and 
early death. Elective and orthopedic corrective surger-
ies are often delayed or canceled due to the difficulty in 
achieving hemostasis. Prior to 1988, the only available 
factor concentrate was aPCC. Although aPCC is effective 
in controlling bleeding episodes and achieving hemostasis 
for surgeries, the reported number of major surgeries is 
relatively minimal. The discovery of plasma derived fac-
tor VIIa and rFVIIa has opened a new era for hemophilia 
patients with inhibitors to have treatment similar to those 
without inhibitors.
The initial constraints of rFVIIa are its short half-life 
and dose-finding. From compassionate-use programs Journal of Blood Medicine 2010:1 45
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and independent studies, rFVIIa at the dose of 90 µg/kg 
appears to be the standard dose commonly used among 
patients. A 2-hour interval is applied for the first 24 to 
48 hours and thereafter increases to 3 to 6 hours according 
to the severity of bleeding manifestation, efficacy of bleed-
ing control, and relief of pain. This regimen can also be 
applied for minor and major surgeries; however, a higher 
initial dose of 120 to 180 µg/kg is required for the major 
surgery. In cases of unexpected bleeding, increasing the 
dose of rFVIIa is suggested. Since some patients may have 
a shorter half-life of rFVIIa (normal children 1.32 hours and 
normal adult 2.72 hours) and a higher clearance rate (normal 
children 67.0 mL/kg/h and normal adult 32.8 mL/kg/h),84,85 
they will require a higher dose (200–300 µg/kg) of rFVIIa to 
achieve the proper clinical response. A neurosurgical resec-
tion of a malignant glioneuronal tumor was reported by 
giving a bolus of 270 µg/kg every 2 hours during the first 
24 hours, followed by 180 µg/kg every 3, 4, and 6 hours at 
days 2 to 3, 4 to 10, and 11 to 15, respectively.86 Therefore, 
it should be noted that the optimal dose of rFVIIa depends 
upon individual half-life and clearance rate of rFVIIa as 
well as the surgical procedure and bleeding sites. Moreover, 
elective surgery should be deferred until the inhibitor level is 
5 BU, and may require the use of high doses of factor VIII 
or IX concentrates in cases of uncontrolled intraoperative or 
postoperative bleeding complications.
The earlier the treatment is given, the more effective 
will be the outcome. The most effective early treatment 
is for home treatment programs. The dose of rFVIIa of 
90 µg/kg, 3 times, 3 hours apart is as effective as a single 
dose of 270 µg/kg. The single dose is convenient especially 
among pediatric age groups who are needle phobic and 
have poor venous access. One study has demonstrated the 
efficacy of effective bleeding control of rFVIIa at the dose 
of 200 µg/kg for mild to moderate bleeding at the muscle 
and joint compared with 200 µg/kg.32
In cases of prophylaxis, the dose of rFVIIa ranging from 
200 to 250 µg/kg/week to 90 to 270 µg/kg daily or every 6 to 
12 hours has been reported. It is an option for preventing 
joint bleeding and protecting joint damage before the initia-
tion of immune tolerance therapy. Recombinant factor VIIa 
is selected due to the awareness of the anamnestic response 
provoked by residual factor VIII antigen contained in aPCC. 
However, the number of patients receiving prophylaxis is 
rather small. Further studies on the most appropriate dose and 
with a larger number of enrolled subjects are warranted.
Interestingly, the incidence of TE events among hemo-
philia patients with inhibitors receiving on-label rFVIIa is 
extremely low, much less than 1%. The analysis of such TE 
events from rFVIIa was complicated by the limited data on 
concomitant and underlying disease risk factors. However, 
the sequential and concomitant therapy of rFVIIa and aPCC 
should be given with caution. Further, clinical manifestations 
and laboratory investigations should be closely monitored 
by hematology experts in the comprehensive hemophilia 
center setting.
The only constraint is the cost of rFVIIa to cover bleed-
ing episodes, surgery and prophylaxis for patients with 
inhibitors, which much higher than for patients without 
inhibitors. However, it has a very low risk, and is conve-
nient and cost-effective in the long term. It will improve the 
physical function and functional status of patients. The cost 
of treating subsequent bleeding episodes at the target joints 
and other related joints, deformity and disability in the fol-
lowing years should be included in the budget calculation. 
A hypothetical model of a hemophilia patient after receiving 
joint replacement with an expected reduction in frequency 
of bleeding of 80% from the assumed 12 bleeding episodes 
per year for 5 years showed that the cost of utilizing rFVIIa 
was cost-effective.87 Moreover, the health related quality 
of life, psychosocial aspects and self-esteem of the patients 
as well as their family members should be included in the 
cost-effectiveness evaluation.
Conclusion
Recombinant factor VIIa has opened a new era of effective 
treatment for hemophilia patients with inhibitors worldwide. 
Hemostasis for bleeding episodes, surgery and prophylaxis 
has been successfully accomplished. The only constraint is 
the extremely high cost of medication. However, it is cost-
effective if the subsequent bleeding episodes at the target 
joints and other related joints, deformity, disability, and 
poor health-related quality of life over the next several years 
are considered in the evaluation.
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